Overview

Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome

Status:
Not yet recruiting

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

The primary objective is to determine the efficacy of Lidocaine Patch 1.8% in reducing the severity of symptoms in participants with moderate-to-severe pain from Carpal Tunnel Syndrome.

Phase:

Phase 4

Details

Lead Sponsor:

John Papakonstantinou, MD

Collaborator:

Scilex Ltd.

Treatments:

Lidocaine